Applications are invited for Postdoctoral Researcher to join the group of Dr. Myriam Charpentier at the John Innes Centre (JIC). Our research focuses on understanding the complex plant signalling networks that govern endosymbiotic interactions between soil microbes and crops. This project aims to characterise a novel plant signalling mechanism that enables nitrogen-fixing rhizobia to successfully colonize root nodule.
About the Charpentier Group:
Bring more to life.
Are you ready to accelerate your potential and make a real difference within life sciences, diagnostics and biotechnology?
At Abcam, one of Danaher’s 15+ operating companies, our work saves lives—and we’re all united by a shared commitment to innovate for tangible impact.
About the Role:
The Business Development Manager role is to source, develop and partner translation opportunity arising from Sanger science for onward development for societal benefit. The role holder will interact with scientific teams, identifying translation opportunity, driving IP strategy, supporting technology development, and building attractive licensing packages ready to partner with industry, R&D partners, or, working with venture formation colleagues, with our spin out companies.
You will be responsible for:
biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases, you’ll be part of a community that prioritizes the human experience, celebrates curiosity, and values every person’s contributions to meaningful progress. That commitment has earned us recognition as Science magazine’s No. 1 Top Employer for five consecutive years, certification as a Great Place to Work® in the U.S., and a place on The Sunday Times Best Places to Work list in the UK.
For patients, for each other, and for the future of science, we’re in. Are you?
At Cancer Research UK, we exist to beat cancer.
Amsbio report how its biospecimens were used in a large-scale immuno-oncology study analysing Fibroblast Activation protein (FAP) expression across 23 tumour types, contributing to new insights into biomarker development for cancer immunotherapies.
About Maxion
Never losing sight of our purpose
Mestag Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of antibody therapeutics targeting cancer and inflammatory disease. Our science is rooted in fibroblast immunology, leveraging cutting-edge biological and translational insights to uncover novel pathways that drive immune modulation in disease.
Mestag is backed by committed leading global investors, has world-class founders and a highly experienced leadership team.